Viatris (NASDAQ:VTRS) announced Thursday that Xulane Lo, a birth control patch designed to deliver a low estrogen dose for women of childbearing potential, reached primary and all secondary endpoints.
The Pfizer (PFE) spinoff noted that Xulane Lo indicated contraceptive
